Compare ACADIA Pharmaceuticals Inc. (ACAD) vs National Beverage Corp. (FIZZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs National Beverage Corp. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while National Beverage Corp. trades at $32.97 (market cap $3.04B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals.
| ACAD | FIZZ | |
|---|---|---|
Market Cap | $4.49B | $3.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $47.69 |
52-Week Low | $20.06 | $31.00 |
Enterprise Value | $3.69B | $2.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
FIZZ (National Beverage Corp.) trades at $32.48, down 2.55% today, with a bearish technical signal and mixed earnings performance. The company maintains strong profitability with 15.56% net margin and 34.03% ROE, though revenue has stagnated around $1.2B annually. Recent news highlights a special $3.25 dividend announcement that boosted shares despite three consecutive quarterly earnings misses.
Outlook remains cautious with 50% of analysts rating Sell amid competitive pressures and consumer weakness. The dividend provides shareholder return but earnings consistency remains a concern. Key risks include tariff impacts and market saturation, while current valuation multiples appear reasonable given profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →
